Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;70(8):715-719.
doi: 10.1136/jclinpath-2016-204162. Epub 2017 Mar 15.

Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer

Min-Kyung Yeo  1   2 , Hee Eun Kim  1 , Sung Hun Kim  3 , Byung Joo Chae  4 , Byung Joo Song  4 , Ahwon Lee  1
Affiliations

Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer

Min-Kyung Yeo et al. J Clin Pathol. 2017 Aug.

Abstract

Aims: Ki-67 is a prognostic marker in breast cancer; however, the use of the Ki-67 labelling index (LI) in clinical practice requires a consistent and easily accessible scoring method. The present study evaluated the use of the free internet-based image analysis program ImmunoRatio to score Ki-67 LI in breast cancer in comparison with manual counting.

Methods: Ki-67 immunohistochemical detection was performed in 577 breast cancer cases, and the Ki-67 LI was determined by ImmunoRatio and manual counting.

Results: The Ki-67 LI determined by ImmunoRatio correlated well with that obtained by manual counting. The concordance rate between ImmunoRatio and manual counting was excellent (κ coefficient of 0.881) at a Ki-67 LI cut-off value of 20%. Cases with high Ki-67 LI by ImmunoRatio were associated with poor overall survival, in particular in the hormone receptor positive group.

Conclusions: The web-based automated image analysis program ImmunoRatio is an attractive alternative to manual counting to determine the Ki-67 LI in breast cancer.

Keywords: BREAST CANCER; DIGITAL PATHOLOGY; PROLIFERATION.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Ki-67 immunohistochemically stained slides were scanned and edited to remove stromal tissue from the tumour nest before the use of ImmunoRatio (A→B, C→D).
Figure 2
Figure 2
Uploaded Ki-67 images were convoluted to ImmunoRatio pseudocoloured (montage) images (A→B, C→D and E→F). ImmunoRatio recognised diaminobenzidine (DAB) and haematoxylin staining separately and scored the Ki-67 labelling index (LI).
Figure 3
Figure 3
Excellent correlation between the Ki-67 labelling index (LI) using ImmunoRatio and manual counting.
Figure 4
Figure 4
Kaplan-Meier overall survival curves based on the Ki-67 labelling index (LI) using ImmunoRatio (A) and manual counting (B) using a 20% cut-off value in a total of 577 breast cancer cases.
Figure 5
Figure 5
In the hormone receptor positive group, Kaplan-Meier curves show a relationship between poor overall survival and high Ki-67 labelling index (LI) (20% cut-off) using ImmunoRatio (A) and manual counting (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dowsett M, Nielsen TO, A'Hern R, et al. . Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656–64. 10.1093/jnci/djr393 - DOI - PMC - PubMed
    1. De Azambuja E, Cardoso F, de Castro G, et al. . Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504–13. 10.1038/sj.bjc.6603756 - DOI - PMC - PubMed
    1. Viale G, Giobbie-Hurder A, Regan MM, et al. . Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569–75. 10.1200/JCO.2008.17.0829 - DOI - PMC - PubMed
    1. Guarneri V, Piacentini F, Ficarra G, et al. . A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009;20:1193–8. 10.1093/annonc/mdn761 - DOI - PubMed
    1. Fasching PA, Heusinger K, Haeberle L, et al. . Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011;11:486 10.1186/1471-2407-11-486 - DOI - PMC - PubMed